Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Carey K. Anders(Duke University), Jonathan S. Serody(University of North Carolina at Chapel Hill), Karen P. McKinnon(Segeberger Kliniken), Hyman B. Muss(University of North Carolina at Chapel Hill), Elizabeth Claire Dees(University of North Carolina at Chapel Hill), Benjamin G. Vincent(University of North Carolina at Chapel Hill), Rachel C. Jankowitz(University of Pennsylvania), Rebecca Kaltman(George Washington University), Alexander C. Robeson(University of North Carolina at Chapel Hill), Katherine E. Reeder‐Hayes(University of North Carolina at Chapel Hill), Lisa A. Carey(University of North Carolina at Chapel Hill), Mark G. Woodcock(Medical College of Wisconsin), Luz Cuaboy(University of North Carolina at Chapel Hill), Vinay Gudena(Centre for the Observation and Modelling of Earthquakes, Volcanoes and Tectonics), Charles M. Perou(University of North Carolina at Chapel Hill), Benjamin C. Calhoun(University of North Carolina at Chapel Hill), Alec D. Wilkinson(University of North Carolina at Chapel Hill), Oleg Kolupaev(University of North Carolina at Chapel Hill), Dante S. Bortone(University of North Carolina at Chapel Hill), Sonia J. Laurie(University of North Carolina at Chapel Hill), Maria J. Sambade(University of North Carolina at Chapel Hill), Kristen Cowens(University of North Carolina at Chapel Hill), Oludamilola Olajide(Rex Hospital), Dominic T. Moore(University of North Carolina at Chapel Hill), Trevor A. Jolly(University of North Carolina at Chapel Hill), Amy Garrett(University of North Carolina at Chapel Hill), Amanda E.D. Van Swearingen(Duke Cancer Institute)
Journal for ImmunoTherapy of Cancer
February 1, 2022
Cited by 28


Related Papers